Table 4.

Determinants of IES-R, avoidance, intrusion and hyperarousal

	IES-R		Avoidance		Intrusion		Hyperarousal
	β	P value	β	P value	β	P value	β	P value
Sex (0=male; 1=female)	0.035	0.576	0.033	0.697	0.042	0.520	0.022	0.724
Age	0.145	0.027	0.100	0.257	0.196	0.004	0.100	0.116
Occupation (0=active worker; 1=non-active worker)	0.143	0.034	0.029	0.748	0.218	0.002	0.146	0.027
Respiratory comorbidities (0=yes; 1=no)	−0.057	0.407	−0.021	0.826	−0.068	0.339	−0.075	0.270
Other comorbidities (0=yes; 1=no)	−0.018	0.778	−0.100	0.26	0.029	0.669	0.019	0.765
Previous psychotherapy (0=yes; 1=no)	0.056	0.380	0.079	0.362	0.065	0.318	0.005	0.936
Prescribed psychoactive drugs (0=yes; 1=no)	−0.18	0.033	−0.174	0.127	−0.192	0.026	−0.132	0.106
Prescribed psychoactive drugs during the COVID-19 pandemic (0=yes; 1=no)	0.067	0.408	0.067	0.543	0.137	0.100	−0.040	0.606
Great concerns about being infected by COVID-19 (0=yes; 1=no)	−0.070	0.291	−0.096	0.284	−0.053	0.434	−0.046	0.470
PHQ-9 score	0.099	0.452	0.101	0.573	0.053	0.692	0.137	0.287
GAD-7 score	0.647	<0.001	0.546	0.001	0.640	<0.001	0.631	<0.001
ISI score	−0.056	0.560	0.010	0.938	−0.052	0.594	−0.126	0.180
Model
Test F	F(12)=18.081; p<0.001		F(12)=7.147; p<0.001		F(12)=17.11; p<0.001		F(12)=19.419; p<0.001
R2	0.753		0.547		0.743		0.766

*Bold values are the statistically significant estimates.

GAD-7, General Anxiety Disorder-7; IES-R, Impact of Event Scale-Revised; ISI, Insomnia Severity Index; PHQ-9, Patient Health Questionnaire-9.